Drugs and Foods on Contraction of Endothelial Cells as a Key Mechanism in Atherogenesis and Treatment of Atherosclerosis with Endothelial-Cell Relaxants (Cyclic AMP Phosphodiesterase Inhibitors)

  • T. Shimamoto
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 60)

Abstract

Sixty years have passed since Anitschkow succeeded in producing an atheroma in his experiment by “cholesterol loading” in rabbits. Until the author (1972)(31, 33) the mechanism of a atherogenes is remained unresolved as a long time enigma.

Keywords

Endothelial Cell Intercellular Space Carbon Particle Thin Filament Internal Elastic Lamina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anitschkow, N.N.: Über die Veränderungen der Kaninchenaorta bei experimentaler Cholesterinsteatose, Beitr. Path. Anat. 56: 379, 1913.Google Scholar
  2. 2.
    Atsumi, T., Isokane, N., Honda, Y., Matsuda, M. and Shimamoto, T.: Studies on atherosclerosis obliterans, tibialis anterior blood flow measured by Xe-133 clearance method and its clinical evaluation, Jap. Circ. J. 35: 1220, 1971.Google Scholar
  3. 3.
    Becker, C.G. and Murphy, G.E.: Demonstration of contractile protein in endothelium and cells of heart valves, endocardium, intima, arteriosclerotic plaques, and Aschoff bodies of rheumatic heart disease. Am. J. Path. 55: 1, 1969.PubMedGoogle Scholar
  4. 4.
    Becker, C.G. and Nachman, R.L.: Contractile proteins of endothelial cells, platelets and smooth muscle. Am. J. Path. 71: 1, 1973.PubMedGoogle Scholar
  5. 5.
    Bennett, H.S.: The concepts of membrane flow and membrane vesiculation as mechanisms for active transport and ion pum pumping. J. Biophysic. and Biochem. Cytol. 2: 99, 1956.CrossRefGoogle Scholar
  6. 6.
    Camerini-Davalos, R.A., Ehrinereich, T., Patel, D. and Oppermann, W.: Nephropathy in spontaneously diabetic mice and its possible prevention by Pyridinolcarbamate (PDC), in Shimamoto, T., Numano, F. and Addison, G.M. editors. Atherogenesis II, Excerpta Medica, 1973, p. 223.Google Scholar
  7. 7.
    Cotton, R.C., Bloor, K. and Archibald, G.: The effect of pyridinolcarbamate treatment on the platelet response to ADP in patients with peripheral atherosclerosis. Brit. J. Surg. 59: 313, 1972.PubMedGoogle Scholar
  8. 8.
    Duguid, J.B.: Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J. Path. Bact. 60: 57, 1948.PubMedCrossRefGoogle Scholar
  9. 9.
    Fukui, K.: Clinical results of pyridinolcarbamate treatment of hemiplegics in Kakeyu Hospital. Atherogenesis, Excerpta Medica, 1969, p. 239.Google Scholar
  10. 10.
    Grafnetter, D., Shimamoto, T. and Numano, F., and Addison, editors. Atherogenesis II, Excerpta Medica, 1973, p. 122.Google Scholar
  11. 11.
    Haust, M.D. and More, R.H.: Development of modern theories on the pathogenesis of atherosclerosis, in Wissler, R.W., and Geer, J.C., editors: The pathogenesis of Atherosclerosis, The Williams & Wilkins Co., Ltd., Baltimore, 1972, p. 1.Google Scholar
  12. 12.
    Insull, W., Jr.: Lipids in arteriosclerotic arterial tissues of man, in Likoff, W., Bernard, L.S. and Insull W., Jr., editors: Atherosclerosis and Coronary Heart Diseases, Grune & Stratton, New York, 1972, p. 20.Google Scholar
  13. 13.
    Januskevichius, Z. and Bloozhas, J. Clinical trial of pyridinolcarbamate. Atherogenesis II, Excerpta Medica, 1973, p. 311.Google Scholar
  14. 14.
    Kaneko, Y. Plasma renin activity and prognosis of essential hypertension. Jap. Circ. J. 36: 995, 1972.Google Scholar
  15. 15.
    Kritchevsky, D. and Tepper, S.A. Influence of pyridinolcarbamate on oxidation of cholesterol by rat liver mitochondria. Arzneimittel-Forschung 21: 146, 1971.PubMedGoogle Scholar
  16. 16.
    Kuo, P.T. Plasma lipids and atherosclerosis, in ibidem, p. 8.Google Scholar
  17. 17.
    Kyusov, V.A., Belousov, Yu B., Martynov, A.I., Koroleva, S.A., Zimin, V.S. and Dudaev, V.A. Treatment by Anginin (pyridinolcarbamate) of the coronary and obliterating atherosclerosis of the lower extremities. Cardiology 11: 39, 1972.Google Scholar
  18. 18.
    Laragh, J.H. Biochemical profiling and the natural history of hypertensive diseases: Low-renin essential hypertension, a benign condition. Circulation 44:. 971, 1971.PubMedGoogle Scholar
  19. 19.
    Lofland, H.B. and Clarkson, T.B. The bi-directional transfer of cholesterol in normal aorta, fatty streaks, and atheromatous plaques. Proc. Soc. Exptl. Biol. Med. 133: 1, 1970.Google Scholar
  20. 20.
    Majino, G., Shea, S.M. and Leventhal, M. Endothelial contraction induced by histamine-type mediators. An electron microscopic study. J. Cell Biol. 42: 647, 1969.CrossRefGoogle Scholar
  21. 21.
    Numano, F., Katsu, K., Takenobu, M., Sagara, A. and Shimamoto, T. Comparative studies on the preventive effect of pyridinolcarbamate and estrogen against aortic and coronary atherosclerosis of cholesterol-fed rabbits. Part II: Histoenzymatic studies. Acta Path., Jap. 21: 193, 1971.Google Scholar
  22. 22.
    Resch, J.A., Okabe, N., Loewenson, R., Kimoto, K., Katsuki, S. and Baker, A.B. A comparative study of cerebral atherosclerosis in a Japanese and Minnesota population. J. Atheroscler. Res. 7: 687, 1967.PubMedCrossRefGoogle Scholar
  23. 23.
    Robertson, A.L. and Khairallah, P.A. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ. Res. 31: 923, 1972.PubMedGoogle Scholar
  24. 24.
    Sano, T., Yamazaki, H. and Shimamoto, T. Enhancement of ADP-induced platelet aggregation by cholesterol and its prevention by pyridinolcarbamate. Thromb. Diath. haemorrh. In press.Google Scholar
  25. 25.
    Shimamoto, T. New concept on atherogenesis and treatment of atherosclerotic diseases with endothelial cell relaxant. Jap. Heart J. 13: 537, 1972.PubMedCrossRefGoogle Scholar
  26. 26.
    Shimamoto, T. The relationship of edematous reaction in arteries to atherosclerosis and thrombosis. J. Atheroscler. Res. 3: 87, 1963.PubMedCrossRefGoogle Scholar
  27. 27.
    Shimamoto, T. Experimental study on atherosclerosis. An attempt at its prevention and treatment. Acta Path. Jap. 19: 15, 1969.PubMedGoogle Scholar
  28. 28.
    Shimamoto, T., Atsumi, T., Yamashita, S., Motomiya, T., Isokane, N., Ishioka, T. and Sakuma, A. Clinical pharmacologic evaluation of the anti-atherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of Atherosclerosis Obliterans. Amer. Heart J. 79: 5, 1970.PubMedCrossRefGoogle Scholar
  29. 29.
    Shimamoto, T., Kobayashi, M. and Numano, F. Infiltration of Y-globulin, fibrinogen and beta-lipoprotein into blood vessel wall by atherogenic stress visualized by immuno-fluorescence. Prof. Jap. Acad. 48: 336, 1972.Google Scholar
  30. 30.
    Shimamoto, T. and Numano, F. Preventive effect of estrogen against cholesterol-induced contraction of arterial endothelial cell. An electron microscopic observation. Proc. Jap. Acad. 48: 742, 1972.Google Scholar
  31. 31.
    Shimamoto, T. and Numano, F. Contraction and relaxation of endothelial cells covering atheroma and their significance. Prof. Jap. Acad. 49: 77, 1973.Google Scholar
  32. 32.
    Shimamoto, T. Numano, F. and Fujita, T. Atherosclerosis-inhibiting effect of an antibradykinin agent, pyridinolcarbamate. Amer. Heart J. 71: 216, 1966.PubMedCrossRefGoogle Scholar
  33. 33.
    Shimamoto, T. and Sunaga, T. Contraction of endothelial cells as a key mechanism in atherogenesis. Prof. Jap. Acad. 48: 633, 1972.Google Scholar
  34. 34.
    Shimamoto, T. and Sunaga, T. The contraction and blebbing of endothelial cells accompanied by acute infiltration of plasma substances into the vessel wall and their prevention, in Shimamoto, T., Numano, F. and Addison, G.M., editor. Atherogenesis II, Excerpta, Medica, 1973, p.3.Google Scholar
  35. 35.
    Shimamoto, T. and Yamazaki, H. Bradykinin-antagonistic anti-inflammatory substance B23 in treatment of angina pectoris. Proc. 3rd Asian-Pacific Cong. Cardiology, Kyoto, 1964, p. 748.Google Scholar
  36. 36.
    Shkhvatsabaya, I.K. Anginin in the treatment of patients with chronic coronary insufficiency. Atherogenesis II, Excerpta Medica, 1973, p. 347.Google Scholar
  37. 37.
    Stamler, J., Berkson, D.N. and Lindberg, H.A. Risk factors: Their role in the etiology and pathogenesis of the atherosclerotic diseases, in Wissler, R.W. and Geer, J.C., editors. The Pathogenesis of Atherosclerosis, The Williams & Wilkins Co., Ltd., Baltimore, 1972, p. 41.Google Scholar
  38. 38.
    Wu, C.C., Huang, T.S. and Hsu, C.J. Prevention of experimental atherosclerosis with pyridinolcarbamate. Amer. Heart J. 77: 657, 1969.PubMedCrossRefGoogle Scholar
  39. 39.
    Yamamura, T. Inhibitory effects of pyridinolcarbamate in angiolathyrism and osteolathyrism, in Shimamoto, T. and Numano, F., editors. Atherogenesis, Excerpta Medica, 1969, p. 29.Google Scholar
  40. 40.
    Yamazaki, H., Takahashi, T. and Shimamoto, T. Inhibitory action of acetylsalicilic acid, pyridinolcarbamate and its derivative on human platelet aggregation. Blood & Vessel 3: 1377, 1972.Google Scholar
  41. 41.
    Yamazawa, S., Shimamoto, T., Hidaka, H. and Mohri, K. The search for anti-atherosclerotic agents. Histological and chemical analysis of the preventive effect of estrogen, progesterone and pyridinolcarbamate on experimentally induced atherosclerosis. Atherogenesis II, Excerpta Medica, 1973, p. 98.Google Scholar

Copyright information

© Plenum Press, New York 1975

Authors and Affiliations

  • T. Shimamoto
    • 1
  1. 1.Institute for Cardiovascular Diseases, Tokyo Ika-ShikaNational University Medical SchoolTokyoJapan

Personalised recommendations